



Genetics, Genomics, and Precision Medicine in Colorectal Cancer

Guest Editors:

Prof. Dr. Enrico Mini

Department of Health Sciences,
University of Florence, Florence,
Italy

Dr. Stefania Nobili

Department of Neurosciences,
Imaging and Clinical Sciences,
"G. d'Annunzio" University of
Chieti-Pescara, Chieti, Italy

Deadline for manuscript
submissions:

15 August 2024

Message from the Guest Editors

Colorectal cancer (CRC) is one of the most common and lethal cancers worldwide, resulting both from germline pathogenic genetic variants and sequential acquisition and accumulation of somatic genomic alterations. Pharmacogenetics and pharmacogenomics affect the choice of therapeutic strategies, directing the selection of specific drugs and their dosing for CRC patients. The role of genetic and genomic determinants as diagnostic, prognostic, and therapeutic biomarkers, as well as targets of drug treatment, is robustly increasing year after year. Approval in past years of anti-EGFR monoclonal antibodies, immune checkpoint inhibitors, and protein kinase inhibitors of oncogenic mutations, such as BRAFV600E, has improved the overall survival of CRC patients that, however, remains limited, especially in the metastatic setting. Thus, more advanced knowledge is needed to improve current clinical results. The aim of this Special Issue is to collect original research articles and reviews on genetics and genomics that might offer relevant insights in the prediction of CRC diagnosis, prognosis, and therapeutic outcome, leading to improvement of precision medicine in CRC.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA

2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
X@JPM_MDPI